Stroke RSS Page 8

Filtered By:
Condition: Atrial Fibrillation
Procedure: Percutaneous Coronary Intervention

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 371 results found since Jan 2013.

Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI - Rationale and study design of the prospective observational multicenter AVIATOR 2 Registry
Publication date: Available online 21 September 2015 Source:American Heart Journal Author(s): Jaya Chandrasekhar, Ioannis Mastoris, Usman Baber, Samantha Sartori, Mikkel Schoos, Sameer Bansilal, George Dangas, Roxana Mehran Background In the era of novel anti-thrombotic therapy, the optimal treatment for patients with non-valvular atrial fibrillation (AF) or flutter undergoing percutaneous coronary intervention (PCI) is undetermined. Study Design The AVIATOR 2 study is a multicenter prospective observational registry that will enroll approximately 2500 patients with non-valvular AF or flutter undergoing PCI star...
Source: American Heart Journal - September 21, 2015 Category: Cardiology Source Type: research

Safety and efficacy of glucose-insulin-potassium treatment in coronary artery bypass graft surgery and percutaneous coronary intervention
The purpose of this meta-analysis was to evaluate protective effects of glucose–insulin–potassium (GIK) on outcomes after coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). We systematically searched Medline/Pubmed, Elsevier, Embase, Web of Knowledge and Google Scholar. A total of 1206 studies were retrieved during the extensive literature search of all major databases; however, 38 trials reporting the end-point of interest were selected. We performed a pooled analysis of outcomes following PCI: incidence of cardiac arrest [odds ratio (OR) of 0.91; 95% confidence interval (CI): ...
Source: Interactive CardioVascular and Thoracic Surgery - October 19, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Ali-Hassan-Sayegh, S., Mirhosseini, S. J., Zeriouh, M., Dehghan, A. M., Shahidzadeh, A., Karimi-Bondarabadi, A. A., Sabashnikov, A., Popov, A.-F. Tags: Congestive Heart Failure Adult Cardiac Source Type: research

Percutaneous left atrial appendage occlusion: Device thrombosis in clopidogrel non-responders
Percutaneous left atrial appendage closure (LAAC) has been recently proposed as a safe and effective strategy to reduce the embolic stroke risk in patients with atrial fibrillation that are not amenable to long lasting oral anticoagulation [1]. After LACC, a temporary double anti-platelets regimen with aspirin and clopidogrel is suggested to prevent closure device thrombosis and enhance its endothelization [2]. Although clopidogrel resistance has been associated with recurrent cardiac events after percutaneous coronary intervention [3], no reports exist concerning the occurrence of LAAC device thrombosis in patients with c...
Source: International Journal of Cardiology - November 24, 2015 Category: Cardiology Authors: Ulrike Ketterer, Giuseppe D´ Ancona, Isabel Siegel, Jasmin Ortak, Hueseyin Ince, Stephan Kische Tags: Correspondence Source Type: research

None-ligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR)
Conclusion Most patients with STEMI not receiving reperfusion therapy had a documented reason. Coronary anatomy not suitable for PCI was the major contributor to ineligibility. In-hospital mortality was higher in patients not receiving reperfusion therapy.
Source: American Heart Journal - November 25, 2015 Category: Cardiology Source Type: research

Association between hyperuricemia and outcomes in patients undergoing percutaneous coronary intervention
Uric acid is the end product of purine catabolism. Lot of previous studies have found that hyperuricemia (HU) as a risk factor for cardiovascular disease such as atrial fibrillation and coronary artery disease [1,2]. Also, HU is a predictor of adverse prognosis in different cardiocerebral disease, such as acute ST segment elevation myocardial infarction, congestive heart failure and acute stroke. However, the predictive value of HU in the prognosis in patients undergoing percutaneous coronary intervention (PCI) is less known.
Source: International Journal of Cardiology - November 28, 2015 Category: Cardiology Authors: Lei Wu, Lan-Ju Yang, Xiao-Yan Meng, Lan-Hua Wang, Yan-Hong Zhou, Tao Liu, Qian-Feng Han, De-Yong Zhang, Heng-Chen Yao Source Type: research

Antithrombotic therapy in patients with combined coronary heart disease and atrial fibrillation.
CONCLUSION: In each clinical scenario, the risks of coronary artery or stent thrombosis in CHD and risks of stroke in AF need to be carefully balanced against the risks of bleeding. We make recommendations for management based on the evidence which is available at this time and indicate the many gaps which are currently being addressed by randomised clinical trials. PMID: 26658287 [PubMed - as supplied by publisher]
Source: Panminerva Medica - December 15, 2015 Category: Journals (General) Tags: Panminerva Med Source Type: research

Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR)
Conclusion Most patients with STEMI not receiving reperfusion therapy had a documented reason. Coronary anatomy not suitable for PCI was the major contributor to ineligibility. In-hospital mortality was higher in patients not receiving reperfusion therapy.
Source: American Heart Journal - January 12, 2016 Category: Cardiology Source Type: research

Usefulness of the CHADSVAS Score to Predict Adverse Outcomes in Patients having Percutaneous Coronary Intervention
The application of the CHA2DS2-VASC score as a novel risk stratification tool for predicting outcome in clinical applications other than atrial fibrillation (AF) and stroke prevention has been previously examined. However its usefulness in a population of patients with coronary artery disease following percutaneous coronary intervention (PCI) has not been explored. We investigated 12,785 consecutive patients who underwent PCI in a tertiary medical center between 4/2004 and 8/2014 (mean follow up 6.5 years) and computed the CHA2DS2-VASC score on their index PCI.
Source: The American Journal of Cardiology - February 16, 2016 Category: Cardiology Authors: Katia Orvin, Tamir Bental, Abid Assali, Eli Israel Lev, Hana Vaknin-Assa, Ran Kornowski Source Type: research

Usefulness of the CHA2DS2VASC Score to Predict Adverse Outcomes in Patients having Percutaneous Coronary Intervention
The application of the CHA2DS2-VASC score as a novel risk stratification tool for predicting outcome in clinical applications other than atrial fibrillation (AF) and stroke prevention has been previously examined. However its usefulness in a population of patients with coronary artery disease following percutaneous coronary intervention (PCI) has not been explored. We investigated 12,785 consecutive patients who underwent PCI in a tertiary medical center between 4/2004 and 8/2014 (mean follow up 6.5 years) and computed the CHA2DS2-VASC score on their index PCI.
Source: The American Journal of Cardiology - February 16, 2016 Category: Cardiology Authors: Katia Orvin, Tamir Bental, Abid Assali, Eli Israel Lev, Hana Vaknin-Assa, Ran Kornowski Source Type: research

Usefulness of the CHA2DS2-VASC Score to Predict Adverse Outcomes in Patients Having Percutaneous Coronary Intervention
The application of the CHA2DS2-VASC score as a novel risk stratification tool for predicting outcome in clinical applications other than atrial fibrillation and stroke prevention has been previously examined. However, its usefulness in a population of patients with coronary artery disease after percutaneous coronary intervention (PCI) has not been explored. We investigated 12,785 consecutive patients who underwent PCI in a tertiary medical center from April 2004 to August 2014 (mean follow-up 6.5 years) and computed the CHA2DS2-VASC score on their index PCI.
Source: The American Journal of Cardiology - February 16, 2016 Category: Cardiology Authors: Katia Orvin, Tamir Bental, Abid Assali, Eli Israel Lev, Hana Vaknin-Assa, Ran Kornowski Tags: Coronary Artery Disease Source Type: research

Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting
Management of antithrombotic therapy in patients with atrial fibrillation (AF) and coronary stenting remains challenging, and there is a need for efficient tools to predict their risk of different types of cardiovascular events and death. Several scores exist such as the CHA2DS2-VASc score, the Global Registry of Acute Coronary Events (GRACE) score, the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score, the Anatomical and Clinical Syntax II Score and the Reduction of Atherothrombosis for Continued Health score.
Source: The American Journal of Cardiology - June 13, 2016 Category: Cardiology Authors: Laurent Fauchier, Coralie Lecoq, Yann Ancedy, Karim Stamboul, Christophe Saint Etienne, Fabrice Ivanes, Denis Angoulvant, Dominique Babuty, Yves Cottin, Gregory Y.H. Lip Tags: Arrhythmias and Conduction Source Type: research

Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
CONCLUSION: The SAFE-A study is the first randomized controlled trial to compare 1-month vs. 6-month P2Y12 inhibitor therapy in combination with aspirin and apixaban, in patients with atrial fibrillation who undergo DES implantation. This study will provide data that may guide the optimal management of triple antithrombotic therapy. PMID: 27443596 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - July 17, 2016 Category: Cardiology Authors: Hoshi T, Sato A, Nogami A, Gosho M, Aonuma K, SAFE-A Investigators Tags: J Cardiol Source Type: research

Influence of undernutrition at admission on clinical outcomes in patients with acute myocardial infarction.
CONCLUSIONS: Nutritional status is a significant prognostic factor in clinical outcomes after MI during hospitalization. Therefore, nutritional assessment and intervention, especially for undernourished MI patients, should be considered. PMID: 27567176 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - August 22, 2016 Category: Cardiology Authors: Yoo SH, Kook HY, Hong YJ, Kim JH, Ahn Y, Jeong MH Tags: J Cardiol Source Type: research

Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban.
This article will introduce and provide context for these RCTs in the contemporary management of arterial and venous thromboembolism in the following underserved areas: Patients with both NVAF and acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI); patients with embolic stroke of undetermined source (ESUS); patients who require transcatheter aortic valve replacement (TAVR); patients with acute or chronic coronary artery disease (CAD; including those with heart failure [HF]); those at risk of or suffering from cancer-associated thrombosis (CAT) and those requiring long-term anticoagulation. It ...
Source: Thrombosis and Haemostasis - September 13, 2016 Category: Hematology Authors: Cappato R, Welsh R Tags: Thromb Haemost Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20